blue and white gradient background
blue and white gradient background
blue and white gradient background

Step Forward
Personalize treatment decisions for RA patients

PrismRA® is a first-of-its kind molecular signature test that gives providers objective insights to drive RA treatment decisions.

The blood test analyzes each patient’s unique molecular signature, predicting if a patient is well suited for TNF inhibitor (TNFi) therapies such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab.1

Now, providers can help improve their patients’ outcomes by identifying those unlikely to respond adequately to TNFi therapies before you prescribe or modify treatment.

Learn how PrismRA was developed
prism network

Results you can act on

PrismRA predicts a patient’s likelihood of non-response to TNFi therapies.

NO SIGNAL

Molecular signal of non-response not detected

HIGH

likelihood of non-response

VERY HIGH

likelihood of non-response

Likelihood of TNFi response

More Likely Less Likely

PrismRA can be easily incorporated into your practice